Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study

References

• The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7
   Google Scholar
• Nestler JE. Insulin resistance and the polycystic ovary syndrome: recent advances. Curr Opin Endocrinol Diabetes 2000;7:345–9
   Google Scholar
• Genazzani AD, Lanzoni C, Ricchieri F, et al. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol 2007;23:146–52
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Battaglia C, Malavasi B, et al. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004;81:114–9
   PubMed Web of Science ®Google Scholar
• Dunaif A, Xia J, Book CB, et al. Excessive insulin receptor serine phosphorylation in cultured fibroblast and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995;96:801–10
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–6
   PubMed Web of Science ®Google Scholar
• Nelson VL, Qin KN, Rosenfield RL. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:5925–33
   PubMed Web of Science ®Google Scholar
• Iuorno MJ, Jakubowicz DJ, Baillargeon JP, et al. Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002;8:417–23
   PubMedGoogle Scholar
• Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci 2003;7:151–9
   PubMedGoogle Scholar
• Genazzani AD, Lanzoni C, Ricchieri F, Valerio M. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome Jasonni. Gynecol Endocrinol 2008;24:139–44
   PubMed Web of Science ®Google Scholar
• Artini PG, Battaglia C, D’Ambrogio G, et al. Relationship between human oocyte maturity, fertilization and follicular fluid growth factors. Hum Reprod 1994;9:902–6
   PubMed Web of Science ®Google Scholar
• Papaleo E, Unfer V, Baillargeon J-P, et al. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009;91:1750–4
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Iuorno MJ, Jakubowicz DJ, et al. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:242–9
   PubMed Web of Science ®Google Scholar
• Baker L, Piddington R, Goldman A, et al. Myo-Inositol and prostaglandin reverse the glucose inhibition of neural tube fusion in cultured mouse embryos. Diabetologia 1990;33:593–6
   PubMed Web of Science ®Google Scholar
• Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000;73:1149–54
   PubMed Web of Science ®Google Scholar
• Haffner SM, Miettinem H, Stern MP. The homeostasis model in the San Antonio Hearth Study. Diabetes Care 1997;20:1087–92
   PubMed Web of Science ®Google Scholar
• De Leo V, La Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. End Rev 2003;24:633–67
   PubMed Web of Science ®Google Scholar
• Hasegawa I, Murakawa H, Suzuki M, et al. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistancerelated polycystic ovary syndrome. Fertil Steril 1999;71:323–7
   PubMed Web of Science ®Google Scholar
• Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83–9
   PubMed Web of Science ®Google Scholar
• Saltiel AR. Second messengers of insulin action. Diabetes Care 1990;13:244–56
   PubMed Web of Science ®Google Scholar
• Papaleo E, Unfer V, Beillargeon JP, et al. Myoinositol in patients with polycystic ovary syndrome a novel method for ovulation induction. Gynecol Endocrinol 2007;23:700–70
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE, et al. Altered D-Chiro-Inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006;29:300–5
   PubMed Web of Science ®Google Scholar
• Goud PT, Goud AP, Oostveldt PV, Dhont M. Presence and dynamic redistribution of type I inositol, 1,4,5-triphosphate receptor in human oocytes and embryos during in-vitro maturation, fertilization and early cleavage division. Mol Hum Reprod 1999;5:441–51
   PubMed Web of Science ®Google Scholar
• Chiu TTY, Rogers MS, Briton-Jones C, Haines C. Effect of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes. Hum Reprod 2003;18:408–16
   PubMed Web of Science ®Google Scholar
• Ciriminna R, Papale ML, Artini PG, et al. Impact of Italian legislation regulating assisted reproduction techniques on ICSI outcomes in severe male factor infertility: a multicentric survey. Hum Reprod 2007;22:2481–7
   PubMedGoogle Scholar